Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cancer drug flush out hidden HIV?

NCT ID NCT07481175

Recruiting now Disease control Sponsor: Thomas Aagaard Rasmussen Source: ClinicalTrials.gov ↗

First seen Mar 23, 2026 · Last updated May 15, 2026 · Updated 13 times

Summary

This study tests whether adding venetoclax, a drug that promotes cell death, to standard HIV treatment can kill cells that harbor dormant HIV. The goal is to shrink the hidden virus reservoir, which is the main barrier to a cure. About 38 adults newly starting HIV therapy will receive venetoclax or standard care, and researchers will measure safety and changes in the reservoir size.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hospital Universitari Germans Trias I Pujol, Department of Infectious Diseases

    RECRUITING

    Badalona, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Infectious Diseases, Q Research

    RECRUITING

    Aarhus, 8200, Denmark

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HIV-1